Cryoport, Inc.
Company Name | Cryoport, Inc. |
Stock Symbol | CYRX |
On July 12, 2023, after market hours, Cryoport announced preliminary second-quarter financial results, and disclosed that its second quarter 2023 total revenue “is expected to be in the range of $56.5 to $57.5 million, representing a decrease of 11%, at the midpoint, compared to the second quarter of 2022.” The Company attributed the shortfall to “a global slowdown in capital equipment investment” as well as “a number of clinical trial start delays and several key customers falling short of their forecasts for the revenue ramp of certain cell and gene therapies.”
On this news, Cryoport’s stock price fell $4.80, or 24.7%, to close at $16.60 per share on July 13, 2023, thereby injuring investors.
Submit Your Information
If you suffered a loss on your Cryoport, Inc. investments or would like to inquire about joining an action to recover your loss under the federal securities laws, please complete the form below. Please note that submission of this form does not by itself form an attorney-client relationship nor does filing out this form mean you have joined any lawsuit.